March confernece call,
Question (internet): When will we see published data on the first 18 patients?
Gary: We are considering a variety of publishing strategies. One thing that we are considering is an update publication on the first two patients that were described in the Lancet. Obviously we've got exciting and good things to talk about with those patients, so that's something we're considering. We're considering some kind of midterm publication on the first 18 patients, though truthfully, with the opportunity of the 20/100 visual acuity patients sort of going on at the same time, to us, really that's the more relevant patient set. So I think what our plan is in the interim, other than the potential for some sort of reviewed and written update related to the first two patients, is that we'll continue to feed you information about these patients periodically on earnings calls and through press releases. We actually have several of our doctors that are speaking at a variety of conferences, including the most prestigious of all the subretinal conferences, which is called the Vail Vitrectomy, so there we have three of our doctors presenting in about two weeks, so they will be talking about what they see in the patients and where they see this trial going. I mean I think it speaks volumes that you've got the world's premier vitreal retinal surgeons walking around, sort of promoting our cell therapy. So I mean in a way, that's the best endorsement you can have. And then I think you should expect to hear something from us once we've got some data around these 20/100 visual acuity patients as well. But I think the presentations that are going to be done at Vail Vitrectomy by Steve and Carl and Jim, I think is very exciting, it's good data, and I think it's a VERY strong endorsement of the potential of this therapy.
AI
